Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) Research & Development: 2012-2025

Historic Research & Development for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $5.1 million.

  • CorMedix's Research & Development rose 601.07% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 155.34%. This contributed to the annual value of $3.9 million for FY2024, which is 70.03% down from last year.
  • Latest data reveals that CorMedix reported Research & Development of $5.1 million as of Q3 2025, which was up 108.69% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Research & Development ranged from a high of $5.1 million in Q3 2025 and a low of $650,988 during Q2 2024.
  • Moreover, its 3-year median value for Research & Development was $2.6 million (2023), whereas its average is $2.6 million.
  • Per our database at Business Quant, CorMedix's Research & Development slumped by 86.42% in 2024 and then skyrocketed by 601.07% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's Research & Development stood at $3.2 million in 2021, then fell by 12.12% to $2.8 million in 2022, then rose by 13.88% to $2.7 million in 2023, then slumped by 72.71% to $1.7 million in 2024, then spiked by 601.07% to $5.1 million in 2025.
  • Its Research & Development stands at $5.1 million for Q3 2025, versus $2.4 million for Q2 2025 and $3.2 million for Q1 2025.